Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual.

Slides:



Advertisements
Similar presentations
Symantec Education Skills Assessment SESA 3.0 Feature Showcase
Advertisements

Patients’ Perspective on HTA and Off-label use David Head MBA Chief Executive RP Fighting Blindness 25th Annual EuroMeeting 4-6 March 2013 RAI, Amsterdam.
Data Monitoring Models and Adaptive Designs: Some Regulatory Experiences Sue-Jane Wang, Ph.D. Associate Director for Adaptive Design and Pharmacogenomics,
Responding to travel managers’ need for and timely reporting Availability.
Office of Information Technology Balancing Technology and Privacy – the Directory Conundrum January 2007 Copyright Barbara Hope and Lori Kasamatsu 2007.
This presentation, including any supporting materials, is owned by Gartner, Inc. and/or its affiliates and is for the sole use of the intended Gartner.
Barry Cherney, Ph.D., Deputy Director DTP/OBP/CDER/ FDA Perspectives on Comparability of Biotechnology Derived Protein Products.
Symantec Managed Security Services The Power To Protect Duncan Evans Director, Cyber Security Services 1.
Clinical Trials in the Age of Personalized Cancer Medicine: The Evolution of a More Efficient, Patient Focused Clinical Research System Session Chair:
GLOBAL ASSESSMENT OF STATISTICAL SYSTEM OF KAZAKHSTAN ZHASLAN OMAROV DEPUTY CHAIRMAN, STATISTICS AGENCY OF REPUBLIC OF KAZAKHSTAN. 4.3.
Type presentation name here in slide master © 2007 SDL. Company Confidential. Forward-looking information is based upon multiple assumptions and uncertainties.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
Introduction to Drug Rediscovery John Lisman Attorney-at-law Lisman Legal Life sciences Insert your logo in this area then delete this text box.
How to audit the role of the vendor in the conduct of outsourced studies Kristel Van de Voorde Director Global Quality Regulatory Compliance Bristol-Myers.
Presenter Name Title Organization Twitter Handle Insert your logo here, then delete text.
©2010 Micron Technology, Inc. All rights reserved. Products are warranted only to meet Micron’s production data sheet specifications. Information, products,
1 “Something to put it in perspective…” Slide Show Name “Something to put it in perspective…” Presented by: Andy Lindsay Parallax, Inc.
President’s Forum and WSML 2012 SYMSTRAT 03: Enterprise Sales Conversations for Virtualization Todd Zambrovitz with guest appearance by Kevin Fiedler 1.
Click to add Presentation Title Arial 32, 5 line max title space line 3, title space line 4, title space line 5 Presenter Title Organization Insert your.
Type presentation name here in slide master © 2007 SDL. Company Confidential. Forward-looking information is based upon multiple assumptions and uncertainties.
1 Optimal Strategies for Preparing Integrated and Clinical Summaries for a New Drug Application: Making it Work Under Any Circumstance Lisa A. Pierchala,
Bayesian approach to equivalence study of medical device 1 1.
Type presentation name here in slide master © 2007 SDL. Company Confidential. Forward-looking information is based upon multiple assumptions and uncertainties.
Sherri de Coronado Enterprise Vocabulary Services NCI Center for Bioinformatics and Information Technology March 11, 2009 A Terminology.
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim.
Making Comments Count for High-Impact Regulations and Guidelines in the US Virginia (Ginny) Beakes-Read Executive Director, Global Regulatory Policy and.
Strategic Analyses and Interpretation: Regulatory Intelligence for Decision Making Amy N. Grant Director, Regulatory Strategy & Science ViroPharma Incorporated.
Good Laboratory Practices and Inspection Readiness Paul Swidersky President/Sr. Consultant Quality Associates, Inc.
Meredith Brown-Tuttle, RAC Director APT Pharmaceuticals, Inc.
Draft White Paper “Protocol Deviations”
DIA ERS SIAC IND CMC eCTD Submissions Part II – IND to NDA
Process-based Metadata From a DIA Presentation: eTMF – Migrating from Paper Trial Master Files to Electronic Eldin Rammell, Managing Director, Rammell.
Protect communications Conditions Actions Exceptions Conditions Actions Exceptions.
Group Sequential Tests for Delayed Responses Christopher Jennison Department of Mathematical Sciences University of Bath Lisa Hampson Department of Mathematics.
Making Comments Count for High-Impact Regulations and Guidelines in Canada, EU, Japan, and US Chairperson: Amy N. Grant Director, Regulatory Strategy &
Gabor Fari Life Sciences Solution Strategist Microsoft Corporation
Session Title Date ǀ Time
- A “Portable” Implementation
Mutagenic Impurities: Guidances Update w/ CMC Perspectives
Presenter Title Organization
Audit of predetermined objectives
Track 11 Symposium 27 June :30 – 3:00 PM
Clinical Trial Disclosure:
Perspective on GCP Warning Letters
Implementing a Successful Corrective and Preventative Action Program
Molly Butler Auditor II Quality Associates, Inc.
Interactive Session: Presentation of Scenarios and Q&A
Community-Based and Cluster-Randomized Studies –‘Pragmatic’ Approaches for Life Cycle Evidence? Florian Eichmann, PhD Principal Scientific Affairs and.
FirstPoint and FirstDoc Application of the DIA EDM Reference Model
Presenter Name Title Organization.
Parallelspace PowerPoint Template for ArchiMate® 2.1 version 1.1
Parallelspace PowerPoint Template for ArchiMate® 2.1 version 2.0
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
PMI® Leadership Institute Meeting 2018―EMEA
PMI® EMEA Congress 2018 Session Title Session Date | Time
Ethics as Culture key elements
Novo Nordisk (Denmark)
Presenter Name Title Organization.
Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug.
1 Session Title 2 line 3 line 4 line
ATTN Presenters – please review and remove this slide from your PowerPoint deck before uploading.
Session Title Date ǀ Time
1 Session Title 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
1 Topic Title First slide 2 line 3 line 4 line
Ethics as Culture key elements
William W. Gregory for the CIOMS MLG Exploratory Team Pfizer Inc
SESSION TITLE Session # <insert number here> Date Month Year
SESSION TITLE Session #<insert number here> Date Month Year
Presentation transcript:

Experiences from building a lessons- learned database for regulatory interactions Åsa Rembratt Sr Reg Intelligence Manager Novo Nordisk A/S 26th Annual EuroMeeting March 2014 ACV, Vienna Austria

Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners.

The RAIL project RAIL = Regulatory Agency Interaction Learnings A lessons-learned database Purpose: To capture and make available new knowledge obtained during agency interactions Target: To optimise knowledge sharing across projects and products in the regulatory organisation and thereby increase the value of efforts made in the regulatory organisation

Topics adressed Input – Timeliness – Quality Content – Granularity – Relevance Output – Access – Searchability Lessons learned database FDA doesn’t want… EMA require… …which enabled submission. Useful info for you Useful info for project X Useful info for me

When is a lessons-learned database a success? When people use it to find information, repeatedly!

Output principles 6

System perception 7

Output, practical solutions 8

Input, timing 9 Sooner… Fresh perspectives Fast access for the organisation to new learnings …or later Time to digest Better knowledge on actual impact on project Goal: Within a month of the minutes/meeting.

Input, quality 10 What to share? Of interest to more than one project Not easily accessible from other sources (guidelines etc.) Quality aspects Correct & consistent level of detail Brief Understandable What if everybody knew but us? This is too project specific!

Ensuring input timeliness & quality 3 rd try 1st try Project champion Entry sparring partner Entry review & approval Trend-spotter Project administrator Alerts & reminders ”Name & shame” statistics 11 2nd try

RAIL content What? –Header giving the message in one sentence –Free text description of learning –Take-home message When? –Date Where? –Country & agency name Who? –Project/product –Contact persons Where can I find more? –References to document handling system –Contact persons –Attachments 12

Output, access 13 Who is the system for? RAIL by regulatory, for regulatory All regulatory, across projects and departments Confidentiality by generalising and/or masking Trend spotting tool for Regulatory intelligence

Thanks! 14 Bente Katafai, RAIL administrator Rasmus Engelbrecht, new RAIL champion Thomas Kühler, RAIL sponsor Merete Schmiegelow, for support All RAIL users at Novo Nordisk